LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

Search

Incyte Corp

Fechado

SetorSaúde

60.82 0.07

Visão Geral

Variação de preço das ações

24h

Atual

Mín

59.15

Máximo

61.11

Indicadores-chave

By Trading Economics

Rendimento

-43M

158M

Vendas

-126M

1.1B

P/E

Médio do Setor

304.25

56.602

EPS

1.16

Margem de lucro

15.025

Funcionários

2,617

EBITDA

-80M

257M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+21.38% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-4.3B

12B

Abertura anterior

60.75

Fecho anterior

60.82

Sentimento de Notícias

By Acuity

26%

74%

74 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2025, 23:20 UTC

Ganhos

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 de mai. de 2025, 23:48 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 de mai. de 2025, 23:43 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 de mai. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 de mai. de 2025, 23:24 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

13 de mai. de 2025, 23:24 UTC

Conversa de Mercado
Ganhos

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 de mai. de 2025, 22:58 UTC

Ganhos

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 de mai. de 2025, 22:58 UTC

Ganhos

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 de mai. de 2025, 22:58 UTC

Ganhos

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 de mai. de 2025, 22:58 UTC

Ganhos

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 de mai. de 2025, 22:38 UTC

Ganhos

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 de mai. de 2025, 22:38 UTC

Ganhos

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 de mai. de 2025, 22:37 UTC

Ganhos

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 de mai. de 2025, 22:36 UTC

Ganhos

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 de mai. de 2025, 22:35 UTC

Ganhos

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 de mai. de 2025, 22:34 UTC

Ganhos

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 de mai. de 2025, 22:33 UTC

Ganhos

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 de mai. de 2025, 22:33 UTC

Ganhos

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 de mai. de 2025, 22:33 UTC

Ganhos

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 de mai. de 2025, 22:30 UTC

Ganhos

Aristocrat Interim Dividend 44 Australian Cents/Share

13 de mai. de 2025, 22:30 UTC

Ganhos

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 de mai. de 2025, 22:29 UTC

Ganhos

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 de mai. de 2025, 22:28 UTC

Ganhos

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 de mai. de 2025, 21:15 UTC

Ganhos

Nu Holdings 1Q Rev $3.2B >NU

13 de mai. de 2025, 21:03 UTC

Principais Notícias

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

13 de mai. de 2025, 20:32 UTC

Ganhos

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 de mai. de 2025, 20:31 UTC

Ganhos

Alcon 1Q Sales $2.45B >ALC.EB

13 de mai. de 2025, 20:30 UTC

Ganhos

Alcon 1Q Rev $2.47B >ALC.EB

13 de mai. de 2025, 20:30 UTC

Ganhos

Alcon 1Q EPS 70c >ALC.EB

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

21.38% parte superior

Previsão para 12 meses

Média 73.86 USD  21.38%

Máximo 95 USD

Mínimo 52 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

6

Comprar

11

Manter

1

Vender

Pontuação Técnica

By Trading Central

59.52 / 62.66Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

74 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation